Trial of Oral Anavex 2-73 in Early Alzheimer’s to Continue with Adjustments

Trial of Oral Anavex 2-73 in Early Alzheimer’s to Continue with Adjustments
Anavex Life Sciences announced plans to continue to screen and enroll patients into its active trials for Alzheimer’s disease and Rett syndrome, in accordance to institutional rules and government guidance related to the COVID-19 pandemic. A Phase 2 study of people with dementia linked to Parkinson's disease is fully enrolled, and the company expects to announce topline results by June. Contingency plans are in place for "remote or virtual assessments" of participants in the Alzheimer's and Parkinson's primary trials, it added, while the Rett trials allow at-home visits. “We understand that some activities will be temporarily slower because of COVID-19, however, our risk-mitigation actions were implemented for every project," Christopher U. Missling, PhD, president and chief executive officer of Anavex, said in a press release. "Anavex’s primary focus is on the safety of all involved and the continued conduct of our clinical programs as we navigate the pandemic together,” Missling added. “Our sites understand why their patients participate in research and are committed to the importance of clinical trials for those patient communities currently without effective treatments.” All trials are testing Anavex 2-73, which was originally developed as a potential disease-modifying therapy for A
Subscribe or to access all post and page content.